Dec 11, 2006
MIV Therapeutics Executes Milestone Agreement to Acquire Biosync Scientific, a Leading Indian Interventional Cardiology Company
Nov 29, 2006
MIV Therapeutics Announces Company’s Biocompatible Stents Matches or
Outperforms World’s Leading Drug-Eluting Stent in Key Categories
Nov 6, 2006
MIV Therapeutics Releases New Corporate Video Presentation on Company's Programs to Develop Advanced HAp-Based Drug-Eluting Cardiovascular Stents
Oct 27, 2006
MIV Therapeutics Announces Timeline for First
Human Implantation of HAp NanoFilm Coated Stent
Oct 23, 2006
MIV Therapeutics to Detail Research Results Showing Excellent Performance of Breakthrough Stent Coatings at TCT Conference
Sep 14, 2006
MIV Therapeutics Names Harvard Interventional Cardiologist Dr. Joseph
Carrozza to Scientific Advisory Board
Industry Authority to Help Guide Development of MIVT’s Unique Coatings for Highly Biocompatible Cardiovascular Stents
Industry Authority to Help Guide Development of MIVT’s Unique Coatings for Highly Biocompatible Cardiovascular Stents
Sep 13, 2006
MIV Therapeutics Enters into Formal Agreement to acquire Vascore Medical Co. Ltd.; a leading Chinese Manufacturer of Advanced Cardiovascular Stents
Aug 25, 2006
MIV Therapeutics Subsidiary Invited to Present Groundbreaking Stroke-
Prevention Device at Top International Symposium
SagaX to Spotlight Latest Developments to Commercialize Unique Implantable Embolic Filter at TCT2006 Conference
SagaX to Spotlight Latest Developments to Commercialize Unique Implantable Embolic Filter at TCT2006 Conference
Aug 23, 2006
MIV Therapeutics to Hold Annual Shareholder Meeting on Thursday, August 24
Company Officers to Review Past Milestone Achievements and Business Initiatives for Coming Year
Company Officers to Review Past Milestone Achievements and Business Initiatives for Coming Year
Aug 14, 2006
MIV Therapeutics to Present Advanced Biocompatible Stent-Coating Technology at International Biomaterials Conference
Senior Scientist Invited to Review Data at 19th International Symposium on Ceramics in Medicine in China
Senior Scientist Invited to Review Data at 19th International Symposium on Ceramics in Medicine in China
Jul 14, 2006
MIV Therapeutics Details Breakthrough Scientific Research in Transcript of Recent Investor Conference Call
Senior Executives Outline Company’s Novel Coronary Stent Coatings to Improve Treatment of Cardiovascular Disease
Senior Executives Outline Company’s Novel Coronary Stent Coatings to Improve Treatment of Cardiovascular Disease
Jul 10, 2006
MIV Therapeutics to Hold Investor Conference Call At 12:00 PM Eastern
Tuesday, July 11
Company President Mark Landy to Update Investors on Key Data Validating MIVT’s Program to Create Safer, Better Coronary Stents
Company President Mark Landy to Update Investors on Key Data Validating MIVT’s Program to Create Safer, Better Coronary Stents
Jul 7, 2006
MIV Therapeutics Updates Investors on Key Scientific Data Supporting Advantages of Company's Biocompatible Stent Technology
Company President Mark Landy to Host July 11 Conference Call to Discuss Breakthrough Data on Hydroxyapatite Safety
Company President Mark Landy to Host July 11 Conference Call to Discuss Breakthrough Data on Hydroxyapatite Safety
Jun 20, 2006
MIV Therapeutics Details Exceptional Performance on HAp Coatings for Coronary Stents at Leading Biomedical Conference
Company Outlines Encouraging New Research Data at Conference of Canadian Medical and Biological Engineering Society
Company Outlines Encouraging New Research Data at Conference of Canadian Medical and Biological Engineering Society
Jun 5, 2006
MIV Therapeutics' Breakthrough Vascular Stent Coating Technology Receives Key Independent Endorsement in New Scientific Study
Independent Research Confirms Primary Safety and Biocompatibility Attributes of Company's Patented HAp Coatings
Independent Research Confirms Primary Safety and Biocompatibility Attributes of Company's Patented HAp Coatings
Apr 4, 2006
MIV Therapeutics Appoints Nationally Ranked Wall Street Medical Device
Analyst and Industry Authority Mark Landy as President
Landy to Bring Strong Institutional Investment and Business Development Background
Landy to Bring Strong Institutional Investment and Business Development Background
Mar 22, 2006
MIVT New Patent Application Targets Worldwide Demand for Safer Drug Delivery Solutions for Chronic Diseases
New Non-Polymeric Drug-Eluting Coatings Offer High Biocompatibility, Drug Storage and Controlled Drug Release
New Non-Polymeric Drug-Eluting Coatings Offer High Biocompatibility, Drug Storage and Controlled Drug Release
Mar 10, 2006
MIV Therapeutics Subsidiary, SagaX Inc., Accelerates Development of Surgical Stroke Prevention Device Towards Commercialization
First Generation Device Could be Ready for Clinical Use Within 14 Months
First Generation Device Could be Ready for Clinical Use Within 14 Months
Mar 9, 2006
MIV Therapeutics SagaX Subsidiary Announces Appointment of New Executives and Technology Specialists
Additions to Sagax Team Strengthens Management and Accelerates Development of Novel Stroke Prevention Device
Additions to Sagax Team Strengthens Management and Accelerates Development of Novel Stroke Prevention Device
Mar 2, 2006
MIVT Invited to Lecture on its Proprietary Biocompatible Coatings for Implanted
Medical Devices and Drug Delivery Systems for the Localized Treatment of Diseases
Feb 3, 2006
MIV Therapeutics Executes Agreement to Collaborate on Future Drug
Eluting Stent Technologies with Sahajanand
Agreement with Stent Manufacturer to Involve Potential Cross-Licensing and Other Development Initiatives
Agreement with Stent Manufacturer to Involve Potential Cross-Licensing and Other Development Initiatives
Jan 31, 2006
MIV Therapeutics to Highlight Latest HAp Advancements at Leading International Scientific Conference on Biomaterials
MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting
MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting
Jan 30, 2006
MIV Therapeutics Shareholders Approve Increase In Authorized Capital to
Allow Development of Proprietary Breakthrough Technology
Company Officers Outline Recent Strategic Achievements and Product Development Initiatives at Shareholders Meeting
Company Officers Outline Recent Strategic Achievements and Product Development Initiatives at Shareholders Meeting
Jan 18, 2006
MIV Therapeutics' Corporate Video Highlights Leadership as Innovator of Novel Safe and Biocompatible Stent Technologies
Online Video Overview Presents MIVT's Proprietary Organic HAp Coating Platform
Online Video Overview Presents MIVT's Proprietary Organic HAp Coating Platform
Jan 4, 2006
MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in
Development of New Generation Biomedical Technologies
Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
